Your tendon has not healed in six months because rest is the wrong prescription
Tendon has poor blood supply and turns over collagen slowly, so it heals in months rather than weeks. Rest does not accelerate it and often makes it worse, because tendon remodels in response to load. In Alfredson's 1998 trial, patients with chronic Achilles tendinosis who had been recommended for surgery returned to pre-injury running after twelve weeks of heavy eccentric loading.
If something has hurt for six months and your plan has been to avoid using it, the plan is the problem. This is the one area of rehab where the intuitive answer and the evidence point in opposite directions.
Why tendon is slow
Muscle is richly vascularised and heals fast. Tendon is not. Blood supply is sparse, metabolic rate is low, and collagen turnover happens over months.
That is the baseline. It means a tendon injury that is four weeks old is not "taking longer than it should." Four weeks is early.
What makes chronic tendon pain different from acute injury is that in most long-standing cases there is no meaningful inflammation to rest. Histology of chronic Achilles and patellar tendon pain shows tendinosis: disorganised collagen, increased ground substance, new blood vessel and nerve ingrowth. It is a failed-healing picture rather than an inflamed one, which is why anti inflammatory strategies and rest so often do nothing over months.
The trial that changed the protocol
In 1998, Alfredson and colleagues took a group of recreational runners with chronic Achilles tendinosis who were on a waiting list for surgery. They were given a heavy-load eccentric calf training programme: three sets of fifteen repetitions, twice daily, seven days a week, for twelve weeks. Load was increased by adding weight once the exercise became painless.
All of them returned to pre-injury running levels. The surgical waiting list group did not.
The detail that matters and gets dropped: the protocol was performed into pain. Patients were told that discomfort during the exercise was expected and not a signal to stop. That is the opposite of what most people do, and it is the part most home attempts get wrong.
Later work using heavy slow resistance training has shown comparable outcomes with a much lower time burden, around three sessions a week rather than fourteen, which is why many clinicians now prefer it.
What actually to do
Load it, progressively, on a schedule. Not by feel. Tendon responds to mechanical load and to nothing else you can do at home.
Expect the timeline to be twelve weeks minimum. If you stop at week four because it still hurts, you have done a third of the intervention and concluded it failed.
Some pain during loading is acceptable in chronic tendinopathy. The usual guidance is that pain should settle within 24 hours and should not be worse session to session. This is very different from acute injury, where that advice does not apply.
Stop stretching it aggressively. Compressive positions at the tendon insertion often aggravate insertional problems.
Get the diagnosis right first. Insertional and mid-portion Achilles problems respond differently, and a partial tear is not tendinosis. If six months have passed, this is worth a proper assessment rather than another protocol from the internet.
BPC-157 and TB-500, and what actually changed in 2026
These two get discussed constantly in tendon contexts, usually with more confidence than the literature supports. Sold together they are widely nicknamed the Wolverine stack. Here is the real state of it, including a regulatory year that most write-ups have not caught up with.
What they are
BPC-157 is a synthetic peptide derived from a sequence identified in gastric juice. The published work is still predominantly animal research, largely rat models: transected Achilles tendon, medial collateral ligament injury, muscle crush injury, gut mucosal damage. Several report accelerated healing and improved tensile strength against controls. Proposed mechanisms involve fibroblast migration and new blood vessel formation.
TB-500 is a synthetic fragment of thymosin beta-4, a naturally occurring peptide involved in actin regulation. Animal work covers wound healing, corneal injury and cardiac repair, with interest centred on cell migration and angiogenesis.
The 2026 regulatory timeline
- February 2026. Both were placed in Category 2 of the FDA's bulk drug substances list, the designation for substances raising significant safety concerns. That barred them from compounding.
- 22 April 2026. Both were removed from Category 2, after the original nominators withdrew their nominations. Removal lifted a barrier; it did not authorise anything.
- 23 July 2026. An FDA advisory committee voted 8 to 6, with one abstention, to recommend adding them to the list of substances compounding pharmacies may prepare.
- Formal notice-and-comment rulemaking is still running, typically 8 to 12 months, before any pharmacy has unambiguous authority.
The distinction almost everyone gets wrong
None of that is FDA approval. It is worth being precise, because the two get used interchangeably online and they are not close.
Approval means a drug was tested in controlled human trials, shown safe and effective for a stated condition, and cleared with an approved label and dose. Compounding permission means a licensed pharmacy may legally prepare a substance. The second says nothing about whether it works.
Neither BPC-157 nor TB-500 is approved for any indication. A committee split 8 to 6 is a narrow recommendation, not a settled scientific verdict.
What human data exists
More than there was, and still thin.
Three human pilot studies have been run on BPC-157: intra-articular knee pain, interstitial cystitis, and an intravenous safety and pharmacokinetics trial. No adverse effects were reported, though these were small and not designed to demonstrate efficacy.
A Phase II placebo-controlled trial in hamstring strain, NCT07437547, is now registered. No results published.
That is the honest position. There is real preclinical work, a regulatory door opening, one proper trial underway, and no published randomised human evidence that either compound heals a tendon. Anyone telling you otherwise is ahead of the data.
Nothing here is a recommendation. The loading protocol above has forty years of human evidence behind it, which is still the difference that matters.
FAQ
How long does a tendon take to heal?
Months, not weeks. Twelve weeks is the standard minimum duration for loading protocols in chronic tendinopathy, and longer-standing cases often take longer.
Should I rest a tendon injury?
Not chronic tendinopathy. Tendon remodels in response to load, and prolonged rest is associated with worse outcomes. Acute ruptures are a different situation entirely.
Is it okay for it to hurt during rehab?
In chronic tendinopathy, generally yes, provided pain settles within 24 hours and does not escalate between sessions. This does not apply to acute injury.
What is eccentric loading?
Loading the tendon during the lengthening phase of a movement, such as lowering slowly from a calf raise. It was the basis of the Alfredson protocol.
Does BPC-157 heal tendons?
There is animal evidence suggesting accelerated tendon healing in rat models, three small human pilot studies, and a registered Phase II hamstring trial with no results yet. No published randomised human evidence shows it heals a tendon.
Is BPC-157 FDA approved?
No. In July 2026 an FDA advisory committee voted 8 to 6 to recommend allowing pharmacies to compound it, which is not the same as approval and is not binding. Neither BPC-157 nor TB-500 is approved for any indication.
What is the Wolverine stack?
The common nickname for BPC-157 and TB-500 used together. It is informal terminology, not a clinical protocol, and no trial has tested the combination.
Sources
- Alfredson H et al. Heavy-load eccentric calf muscle training for the treatment of chronic Achilles tendinosis. American Journal of Sports Medicine, 1998.
- Kongsgaard M et al. Corticosteroid injections, eccentric decline squat training and heavy slow resistance training in patellar tendinopathy. Scandinavian Journal of Medicine & Science in Sports, 2009.
- FDA bulk drug substances list, Category 2 removal of BPC-157 and TB-500, 22 April 2026.
- FDA advisory committee vote on compounding, 23 July 2026, 8 to 6 with one abstention.
- ClinicalTrials.gov NCT07437547, Phase II placebo-controlled trial of BPC-157 in hamstring strain. No results published.
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing, 2025.
Get the next one
Get new pieces as they go up. No more than one email a month, and nothing sold to you.
Unsubscribe in one click. We never sell or share the list.